About the author Lori Conaway

CSafe Expands Executive Team with Chief Financial Officer

CSafe Expands Executive Team with Chief Financial Officer

 

MONROE, Ohio, September 12, 2023 – CSafe, the largest active and passive temperature-controlled shipping solutions provider for the biopharmaceutical industry, announced today that Anthony Pishotti has joined the team as Chief Financial Officer (CFO). This expansion of the executive leadership team will accelerate CSafe’s mission to ensure patients around the world receive the medicines and treatments they need. 

Mr. Pishotti brings over 20 years of deep operating, financial, and commercial leadership across the Warehouse Automation, Material Handling, Aircraft Engines, Rail, and Energy industries. He rose through the finance teams at multiple high performing organizations, serving in CFO positions with Honeywell, GE Aviation, and GE Transportation.  A true cross-functional executive, he was most recently the VP of Global Sales at Honeywell International.  In this role he was responsible for a $2 billion warehouse automation business with 100+ global sellers aimed at expanding into new markets, growing share of wallet, and introducing new solution offerings. 

“We are pleased to welcome Anthony to the CSafe team. His experience leading global companies through best-in-class financial planning, commercial operations, and M&A integrations will be invaluable,” said Patrick Schafer, CEO of CSafe. “As we rapidly introduce innovative products and real-time tracking solutions to our active and passive containers, there is no doubt that Anthony’s leadership will accelerate our growth.” 

In this role, Mr. Pishotti will lead the company’s Finance team, guide strategic planning and annual budgeting process, partner with the business on Merger and Acquisition opportunities, and actively support commercial efforts.   

Mr. Schafer added, “CSafe’s commitment to innovation has propelled us into an exciting time for growth. As we continue to deliver comprehensive, high performing solutions for our pharmaceutical customers, we look forward to Anthony’s leadership and support in creating value for all stakeholders.”

CSafe Announces Plans for First Frozen Active Temperature-Controlled Container

CSafe Announces Plans for First Frozen Active Temperature-Controlled Container

MONROE, Ohio, July 11, 2023 – CSafe, the largest provider of a complete range of active and passive temperature-controlled shipping solutions for the pharmaceutical industry, announced today that the company will expand its active bulk air cargo container portfolio to integrate a new -20°C temperature setpoint for the CSafe RKN.

The company will begin offering CSafe RKNs with the new frozen temperature setpoint on the control panel early next year. The CSafe RKN design requires minimal adjustment to accommodate the new -20°C temperature setpoint, limiting the need for additional customer training to take advantage of the new temperate profile.

Tom Weir, COO CSafe “Our engineering team designed our RKN in a way that we could easily add frozen temperature setpoints in the future,” said CSafe Chief Operating Officer, Tom Weir. “Every CSafe RKN is built with patented high-performance VIP insulation and an innovative air recirculation system that envelops the entire payload. Combined with our industry-leading preventive maintenance rebuild program and support from our global service network, these technologies and service programs have delivered reliable temperature control and exceptional battery life for 15 years.”

Patrick Schafer, CEO CSafe “This expansion of our high-performing active bulk air cargo portfolio is yet another example of CSafe’s on-going commitment to delivering new innovations to meet the changing needs of the biopharma industry,” added CSafe Chief Executive Officer, Patrick Schafer. “We are passionate about ensuring life-saving and life-enhancing medicines can be safely delivered to patients around the world.  With this latest capability, CSafe offers an unmatched range of temperature profiles that can meet virtually every requirement for customers shipping these high-value therapies.”

CSafe RKNs with the -20°C setpoint capability will be available for lease in early 2024. Additional details include:

  • Predictive and real-time analysis pre- and post-shipment to assess lane risk based on external data sources, such as flight tracking, inclement weather, etc.;
  • total visibility to conditional data in addition battery level percentage and door open/close events;
  • sustainable design providing a lower energy active system to maintain optimum performance, while still operating at the broadest RKN ambient operating temperature range in the industry; and
  • optimal footprint for all wide-bodied aircraft, ground transportation and warehouse operations.

CSafe Providing Sustainable Thermal Protection for Vyjuvek Gene Therapy from Krystal Biotech

CSafe Providing Sustainable Thermal Protection for Vyjuvek Gene Therapy from Krystal Biotech

Monroe, OH -May 22, 2023 – CSafe, the largest provider of a complete range of active and passive temperature-controlled shipping solutions for the pharmaceutical industry, is honored to announce an innovative program for Krystal Biotech that provides the cold chain solution for Krystal’s Vyjuvek gene therapy.

CSafe’s custom thermal shipper for Krystal maintains -20°C throughout the product journey to help ensure that doses of Vyjuvek reach clinicians and patients safely. In addition to best-in-class Vacuum Insulated Panel (VIP) technology, the customized CSafe CGT Ultra solution features simplified product handling.

The Vyjukek supply chain is further optimized by utilizing CSafe’s Retest & Reuse program. This approach features reusable shippers that maintain the highest level of thermal performance. When customers participate in CSafe’s reuse program, our highly qualified team inspects, cleans and thermally requalifies the insulation and shippers to assure thermal integrity prior to reuse. This fully managed, end-to-end solution reduces unnecessary landfill waste and is an efficient, effective, and environmentally responsible packaging program.

“Cell and gene therapies are a core focus for CSafe, and we’re honored to support Krystal Biotech and their transformative treatment,” said Patrick Schafer, CSafe CEO. “Using innovative engineering concepts, the CSafe team is able to stay at the forefront of both biopharmaceutical innovation and sustainability approaches. We’re pleased to support the most advanced therapies with the most advanced solutions for the sustainable, high-performance cold chain.”